Journal Mobile Options
Table of Contents
Vol. 18, No. 2, 2004
Issue release date: August 2004
Dement Geriatr Cogn Disord 2004;18:217–226

Ginkgo biloba Compared with Cholinesterase Inhibitors in the Treatment of Dementia: A Review Based on Meta-Analyses by the Cochrane Collaboration

Kurz A. · van Baelen B.
aDepartment of Psychiatry and Psychotherapy, Technical University Munich, Munich, Germany; bMedisearch International, Mechelen, Belgium

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Data were derived from the Cochrane Collaboration meta-analyses of the efficacies of ginkgo, donepezil, rivastigmine and galantamine on changes in cognitive function in patients with dementia and, where necessary, were transformed to standardized mean differences. The proportion of patients discontinuing trials was used as a proxy measure of tolerability. Outcomes were assessed after 6 months of treatment. Trial data for cholinesterase inhibitors were more consistent than those for ginkgo, particularly regarding patient populations and outcome measures. Significant benefits on cognition vs. placebo were seen with donepezil, 5 and 10 mg, rivastigmine, 6–12 mg, and galantamine, 16 and 24 mg. Significant benefit vs. placebo with ginkgo was seen only when all doses were pooled. Similar proportions of patients discontinued treatment with ginkgo and placebo. Cholinesterase inhibitors were also well tolerated, although a significantly greater proportion of patients receiving active treatment discontinued vs. placebo with some doses. An evidence-based medicine approach, taking into account the quality of clinical trials, is essential when assessing the safety and efficacy of medications.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Hendrie HC: Epidemiology of dementia and Alzheimer’s disease. Am J Geriatr Psychiatry 1998;6:S3–S18.
  2. Lobo A, Launer LJ, Fratiglioni L, Andersen K, Di Carlo A, Breteler MM, Copeland JR, Dartigues JF, Jagger C, Martinez-Lage J, Soininen H, Hofman A: Prevalence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000;54:S4–S9.
  3. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS): Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Lancet 2001;357:169–175.
  4. McKenna DJ, Jones K, Hughes K: Efficacy, safety, and use of Ginkgo biloba in clinical and preclinical applications. Altern Ther Health Med 2001;7:70–90.
  5. Yoshikawa T, Naito Y, Kondo M: Ginkgo biloba leaf extract: Review of biological actions and clinical applications. Antioxid Redox Signal 1999;1:469–480.
  6. Christen Y, Maixent JM: What is Ginkgo biloba extract EGb 761? An overview – From molecular biology to clinical medicine. Cell Mol Biol 2002;48:601–611.
  7. Birks J, Grimley Evans J, Van Dongen M: Ginkgo biloba for cognitive impairment and dementia (Cochrane Review); in: Cochrane Library, Issue 2, 2003. Update Software.
  8. Watkins RW: Herbal therapeutics: The top 12 remedies. Emerg Med 2002;34:12–19.
  9. Clegg A, Bryant J, Nicholson T, McIntyre L, De Broe S, Gerard K, Waugh N: Clinical and Cost-Effectiveness of Donepezil, Rivastigmine and Galantamine for Alzheimer’s Disease. London, National Institute for Clinical Excellence, 2001.
  10. Husereau D, Wolfson C, Shukla VK: Drug Treatments for Alzheimer’s Disease: Efficacy, Outcome Measurements and Cost-Effectiveness. Technology Overview No 4. Ottawa, Canadian Coordinating Office for Health Technology Assessment (CCOHTA), 2001.
  11. Doody RS, Stevens JC, Beck C, Dubinsky RM, Kaye JA, Gwyther L, Mohs RC, Thal LJ, Whitehouse PJ, DeKosky ST, Cummings JL: Practice parameter: Management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1154–1166.
  12. Birks J, Grimley Evans J, Iakovidou V, Tsolaki M: Rivastigmine for Alzheimer’s disease (Cochrane Review); in: Cochrane Library, Issue 2, 2003. Update Software.
  13. Birks JS, Melzer D, Beppu H: Donepezil for mild and moderate Alzheimer’s disease (Cochrane Review); in: Cochrane Library, Issue 2, 2003. Update Software.
  14. Olin J, Schneider L: Galantamine for Alzheimer’s disease (Cochrane Review); in: Cochrane Library, Issue 2, 2003. Update Software.
  15. Deeks J: Statistical Methods Programmed in MetaView. Oxford, Cochrane Library, 1999.
  16. DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986;7:177–188.
  17. Toulouse E, Piéron H: Toulouse-Piéron. Prueba Perceptiva y de Atención. Madrid, TEA Ediciones, 1986.
  18. Robinson RA: Current Achievements in Geriatrics. London, Cassell, 1964, pp 190–203.
  19. Wechsler D: A standardized memory scale for clinical use. J Psychol 1945;19:87–95.
  20. Rosen WG, Mohs RC, Davis KL: A new rating scale for Alzheimer’s disease. Am J Psychiatry 1984;141:1356–1364.
  21. Folstein MF, Folstein SE, McHugh PR: ‘Mini-mental state’. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–198.
  22. Allain H, Raoul P, Lieury A, LeCoz F, Gandon JM, d’Arbigny P: Effect of two doses of Ginkgo biloba extract (EGb 761) on the dual-coding test in elderly subjects. Clin Ther 1993;15:549–558.
  23. Chartres JP, Bonnan P, Martin G: Reduction de posologie de médicaments psychotropes chez des personnes agées vivant en institution. Etude à double-insu chez des patients prenant soit de l’extrait de Ginko biloba 761 soit du placebo. Psychol Med 1987;19:1365–1375.
  24. Hofferberth B: The efficacy of EGb 761 in patients with senile dementia of the Alzheimer type. A double-blind, placebo-controlled study on different levels of investigation. Hum Psychopharmacol 1994;9:215–222.
  25. Maurer K, Ihl R, Dierks T, Frolich L: Clinical efficacy of Ginkgo biloba special extract EGb 761 in dementia of the Alzheimer type. J Psychiatr Res 1997;31:645–655.
  26. Hartmann A, Frick M: Wirkung eines Ginkgo-Spezial-Extraktes auf psychometrische Parameter bei Patienten mit vaskulär bedingter Demenz. Münch Med Wochenschr 1991;133:S23–S25.
  27. Haase J, Halama P, Horr R: Effectiveness of brief infusions with Ginkgo biloba special extract EGb 761 in dementia of the vascular and Alzheimer type. Z Gerontol Geriatr 1996;29:302–309.
  28. Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV: Efficacy of galantamine in probable vascular dementia and Alzheimer’s disease combined with cerebrovascular disease: A randomised trial. Lancet 2002;359:1283–1290.
  29. Brautigam MRH, Blommaert FA, Verleye G, Castermans J, Jansen Steur ENH, Kleijnen J: Treatment of age-related memory complaints with Ginkgo biloba extract: A randomized, placebo-controlled study. Phytomedicine 1998;5:425–434.

    External Resources

  30. van Dongen MC, van Rossum E, Kessels AG, Sielhorst HJ, Knipschild PG: The efficacy of Ginkgo for elderly people with dementia and age-associated memory impairment: New results of a randomized clinical trial. J Am Geriatr Soc 2000;48:1183–1194.
  31. Le Bars PL, Katz MM, Berman N, Itil TM, Freedman AM, Schatzberg AF: A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. JAMA 1997;278:1327–1332.
  32. Clegg A, Bryant J, Nicholson T, McIntyre L, De Broe S, Gerard K, Waugh N: Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer’s disease. A systematic review. Int J Technol Assess Health Care 2002;18:497–507.
  33. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ: Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 1996;17:1–12.
  34. National Institute for Clinical Excellence: Guidance on the use of Donepezil, Rivastigmine and Galantamine for the Treatment of Alzheimer’s Disease. London, National Institute for Clinical Excellence, 2001.
  35. Wolfson C, Oremus M, Shukla V, Momoli F, Demers L, Perrault A, Moride Y: Donepezil and rivastigmine in the treatment of Alzheimer’s disease: A best-evidence synthesis of the published data on their efficacy and cost-effectiveness. Clin Ther 2002;24:862–886.
  36. Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E: A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease. Neurology 2001;57:613–620.
  37. Meyer JS, Chowdhury MH, Xu G, Li YS, Quach M: Donepezil treatment of vascular dementia. Ann NY Acad Sci 2002;977:482–486.
  38. Grässel E: Einfluß von Ginkgo-biloba-Extrakt auf die geistige Leistungsfähigkeit. Fortschr Med 1992;110:73–76.
  39. Kanowski S, Herrmann WM, Stephan K, Wierich W, Hörr R: Proof of efficacy of the Ginkgo biloba special extract EGb 761 in outpatients suffering from primary degenerative dementia of the Alzheimer type and multi-infarct dementia. Pharmacopsychiat 1996;29:47–56.
  40. Raskind MA, Peskind ER, Wessel T, Yuan W: Galantamine in AD. A 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology 2000;54:2261–2268.
  41. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Parys W, Ding C: A 5-month, randomized, placebo-controlled trial of galantamine in Alzheimer’s disease. Neurology 2000;54:2269–2276.
  42. Wilcock GK, Lilienfeld S, Gaens E: Efficacy and safety of galantamine in patients with mild to moderate Alzheimer’s disease: Multicentre randomised controlled trial. BMJ 2000;321:1445–1449.
  43. Corey-Bloom J, Anand R, Veach J: A randomized trial evaluating the efficacy and safety of ENA-713 (Rivastigmine tartrate), a new cholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s disease. Int J Geriatr Psychopharmacol 1998;1:55–65.
  44. Rösler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, Stähelin HB, Hartmann R, Gharabawi M: Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: International randomised controlled trial. BMJ 1999;318:633–640.
  45. Rai GS, Shovlin C, Wesnes KA: A double-blind, placebo-controlled study of Ginkgo biloba extract ("Tanakan") in elderly outpatients with mild to moderate memory impairment. Curr Med Res Opin 1991;12:350–355.
  46. Tariot P, Perdomo CA, Whalen E, Sovel MA, Scham EM: Age is not a barrier to donepezil treatment of Alzheimer’s disease in the long-term care setting. Int Psychogeriatr 1999;11(suppl 1):134.
  47. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT: A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Neurology 1998;50:136–145.
  48. Burns A, Rossor M, Hecker J, Gauthier S, Petit H, Möller HJ, Rogers SL, Friedhoff LT: The effects of donepezil in Alzheimer’s disease – results from a multinational trial. Dement Geriatr Cogn Disord 1999;10:237–244.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50